argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024

Rhea-AI Summary

argenx (Euronext & Nasdaq: ARGX), a global immunology company, has announced it will host a conference call and audio webcast on Thursday, October 31, 2024 at 1:30 PM CET (8:30 AM ET) to discuss its third quarter 2024 financial results and provide a business update. The webcast will be accessible through the Investors section of argenx's website, with a replay available for approximately one year. The company has provided international dial-in numbers for Belgium, France, Netherlands, United Kingdom, United States, Japan, and Switzerland.

October 24, 2024

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, October 31, 2024 at 1:30 PM CET (8:30 AM ET) to discuss its third quarter 2024 financial results and provide a business update.

A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation.

Dial-in numbers:

Belgium         32 800 50 201
France                 33 800 943355
Netherlands         31 20 795 1090
United Kingdom 44 800 358 0970
United States         1 888 415 4250
Japan                 81 3 4578 9081
Switzerland         41 43 210 11 32

Use the access code 3810049 to join the call. Please dial in 15 minutes prior to the live call.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker in the U.S., Japan, Israel, the EU, the UK, Canada and China. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, X/Twitter, Instagram, Facebook, and YouTube.

For further information, please contact:

Media:

Ben Petok
bpetok@argenx.com

Investors:

Alexandra Roy (US)
aroy@argenx.com

Lynn Elton (EU)
lelton@argenx.com

FAQ

When will argenx (ARGX) report Q3 2024 earnings?

argenx will report its third quarter 2024 financial results on Thursday, October 31, 2024, at 1:30 PM CET (8:30 AM ET).

How can I access argenx (ARGX) Q3 2024 earnings call?

You can access the earnings call through the webcast on argenx's website (Investors section) or by dialing in using country-specific numbers with access code 3810049.

How long will argenx (ARGX) Q3 2024 earnings call replay be available?

The webcast replay will be available on the argenx website for approximately one year following the presentation.